Dr. Tania Schink

  • Since March 2023 Scientific expert im Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency's (EMA)
  • Since 2022 Senior Scientist (Expert)
  • since April 2010 Head of "Drug Safety" unit
  • since February 2009 Research Associate at the Leibniz Institute for Prevention Research and Epidemiology - BIPS
  • June 2007 Doctorate in Medical Sciences, Charité, Humboldt University Berlin
  • November 2007 Master of Public Health, Harvard School of Public Health, Boston, USA; Concentration: Quantitative Methods (Epidemiology & Pharmacoepidemiology), Focus: Decision Sciences
  • March 2001 - February 2008 Research Associate at the Department of Biostatistics and Clinical Epidemiology at the Charité, Universitätsmedizin Berlin
  • January 2000 - December 2000 Research Associate at the Department of Medical Computer Sciences, Biostatistics and Epidemiology at the Ludwig-Maximilians-Universität, München
  • November 1999 Diplom in Statistics, Ludwig-Maximilians-University, Munich

  • Drug and vaccine safety, esp. during pregnancy
  • Use of electronic health record data for pharmacoepidemiologogical research
  • Causal Inference

    ORCID logo

    Selected BIPS-Publications

  • Articles with peer review

  • García Rodríguez LA, Ruigómez A, Schink T, Voss A, Smits E, Swart KM, Balabanova Y, Suzart-Woischnik K, Brobert G, Herings R. Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: Analysis of routine clinical data from four countries. Expert Opinion on Drug Safety. 2023;22(6):493-500.
    https://doi.org/10.1080/14740338.2023.2181334
  • Haug U, Kollhorst B, Schink T, Thöne K, Dathe K, Schaefer C, Onken M. Investigating drug safety in pregnancy based on the German Pharmacoepidemiological Research Database (GePaRD): A proof-of-concept analysis on the association between valproate and spina bifida. Pharmacoepidemiology and Drug Safety. 2023;32(2):148-157.
    https://doi.org/10.1002/pds.5573
  • Platzbecker K, Müller-Fielitz H, Foraita R, Koepp MJ, Voss A, Pflock R, Linder R, Pigeot I, Schink T, Schwaninger M. In atrial fibrillation epilepsy risk differs between oral anticoagulants: Active comparator, nested case control study. Europace. 2023;25(5):euad087.
    https://doi.org/10.1093/europace/euad087
  • Voss A, Smits E, Swart KM, Balabanova Y, Brobert G, Suzart-Woischnik K, Herings R, Schink T, Haug U. Time trends in patient characteristics of new rivaroxaban users with atrial fibrillation in Germany and the Netherlands. Drugs - Real World Outcomes. 2023;10(2):215-224.
    https://doi.org/10.1007/s40801-022-00350-2
  • Willame C, Dodd C, Duran C, Elbers R, Gini R, Bartolini C, Paoletti O, Wang L, Ehrenstein V, Kahlert J, Haug U, Schink T, Diez-Domingo J, Mira-Iglesias A, Carreras JJ, Vergara-Hernández C, Giaquinto C, Barbieri E, Stona L, Huerta C, Martin-Perez M, Garcia-Poza P, de Burgos A, Martinez-Gonzalez M, Bryant V, Villalobos F, Pallejà-Millán M, Aragon M, Carreras JJ, Souverein P, Thurin N, Weibel D, Klungel O, Sturkenboom MCJM. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - An ACCESS cohort study. Vaccine. 2023;41(1):251-262.
    https://doi.org/10.1016/j.vaccine.2022.11.031
  • Asendorf M, Reinold J, Schink T, Kollhorst B, Haug U. Abbildbarkeit des sozioökonomischen Status in der pharmakoepidemiologischen Forschungsdatenbank GePaRD: Beschreibung und Anwendung am Beispiel des Zusammenhangs mit Adipositas. GMS Medizinische Informatik, Biometrie und Epidemiologie. 2022;18(1):Doc02.
    https://doi.org/10.3205/mibe000235
  • Platzbecker K, Voss A, Reinold J, Elbrecht A, Biewener W, Prieto-Alhambra D, Jödicke A, Schink T. Validation of algorithms to identify acute myocardial infarction, stroke, and cardiovascular death in German health insurance data. Clinical Epidemiology. 2022;14:1351-1361.
    https://doi.org/10.2147/CLEP.S380314
  • Schäfer W, Reinders T, Schink T. Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions. Vaccine. 2022;40(14):2168-2172.
    https://doi.org/10.1016/j.vaccine.2022.02.072
    https://repository.publisso.de/resource/frl:6432144
  • Schink T, Princk C, Braitmaier M, Haug U. Use of combined oral contraceptives and risk of venous thromboembolism in young women: A nested case-control analysis using German claims data. BJOG: An International Journal of Obstetrics & Gynaecology. 2022;129(13):2107-2116.
    https://doi.org/10.1111/1471-0528.17268
  • Thurin N, Pajouheshina R, Roberto G, Dodd C, Hyeraci G, Bartolini C, Paoletti O, Nordeng H, Wallach-Kidemoes H, Ehrenstein V, Dudukina E, MacDonald T, De Paoli G, Loane M, Damase Michel C, Beau A-B, Droz-Perroteau C, Lassalle R, Bergmann J, Swart K, Schink T, Cavero-Carbonell C, Barrachina-Bonet L, Gomez-Lumbreras A, Giner-Soriano M, Aragon M, Neville A, Puccini A, Pierini A, Ientile V, Trifirò G, Rissmann A, Leinonen M, Martikainen V, Jordan S, Thayer D, Scanlon I, Georgiou M, Cunnington M, Swertz M, Sturkenboom MCJM, Gini R. From inception to ConcePTION: Genesis of a network to support better monitoring and communication of medication safety during pregnancy and breastfeeding. Clinical Pharmacology and Therapeutics. 2022;111(1):321-331.
    https://doi.org/10.1002/cpt.2476
  • Schäfer W, Wentzell N, Schink T, Haug U. Characterization of pregnancies exposed to St. John's wort and their outcomes: A claims data analysis. Reproductive Toxicology. 2021;102:90-97.
    https://doi.org/10.1016/j.reprotox.2021.04.005
    https://repository.publisso.de/resource/frl%3A6428346
  • Gini R, Sturkenboom MCJM, Sultana J, Cave A, Landi A, Pacurariu A, Roberto G, Schink T, Candore G, Slattery J, Trifirò G, on behalf of the Working Group 3 of ENCePP. Different strategies to execute multi-database studies for medicines surveillance in real-world setting: A reflection on the European model. Clinical Pharmacology and Therapeutics. 2020;108(2):228-235.
    https://doi.org/10.1002/cpt.1833
  • Reutfors J, Cesta CE, Cohen JM, Bateman BT, Brauer R, Einarsdóttir K, Engeland A, Furu K, Gissler M, Havard A, Hernandez-Diaz S, Huybrechts KF, Karlstad Ø, Leinonen MK, Li J, Man KK, Pazzagli L, Schaffer A, Schink T, Wang Z, Yu Y, Zoega H, Bröms G. Antipsychotic drug use in pregnancy: A multinational study from ten countries. Schizophrenia Research. 2020;220:106-115.
    https://doi.org/10.1016/j.schres.2020.03.048
  • Schink T, Wentzell N, Dathe K, Onken M, Haug U. Estimating the beginning of pregnancy in German claims data: Development of an algorithm with a focus on the expected delivery date. Frontiers in Public Health. 2020;8:350.
    https://doi.org/10.3389/fpubh.2020.00350
  • Wentzell N, Haug U, Schink T, Engel S, Liebentraut J, Linder R, Onken M, Schaefer C, Dathe K. Valproatverordnungen bei Mädchen und Frauen im gebärfähigen Alter in Deutschland: Untersuchung zeitlicher Trends basierend auf Versichertendaten. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(8):1022-1029.
    https://doi.org/10.1007/s00103-018-2768-1
  • Wentzell N, Schink T, Haug U, Ulrich S, Niemeyer M, Mikolajczyk R. Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data. Pharmacoepidemiology and Drug Safety. 2018;27(9):1005-1010.
    https://doi.org/10.1002/pds.4588
    https://repository.publisso.de/resource/frl%3A6417552
  • Articles without peer review

  • Schink T, Princk C, Haug U. Risiko venöser Thromboembolien bei Einnahme von kombinierten hormonalen Kontrazeptiva. Bulletin zur Arzneimittelsicherheit - Informationen aus BfArM und PEI. 2021;2:13-16.
    https://www.bfarm.de/DE/Aktuelles/Publikationen/Bulletin/Ausgaben/_node.html
  • Guidelines and reports

  • The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), in collaboration with Ehrenstein V, Margulis A, Schink T, De Vries C, Petersen I, Thurin N, Nordeng H. Annex 2 - Guidance on methods for the evaluation of medicines in pregnancy and breastfeeding. Amsterdam, The Netherlands 2022.
    https://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
  • The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), in collaboration with Pacurariu A, Kirchmayer U, Arana A, Schink T. Bias. Amsterdam, The Netherlands 2022.
    https://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
  • The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), in collaboration with Hall G, Hallas J, Schink T. Definition and validation of drug exposure, outcomes and covariates. Amsterdam, The Netherlands 2022.
    https://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
  • The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), in collaboration with Hall G, Schink T, Li X. Positive and negative control exposures and outcomes. Amsterdam, The Netherlands 2022.
    https://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
  • The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), in collaboration with Schink T, Hall G, Leacy F, Hallas J, Kurz X. The target trial emulation. Amsterdam, The Netherlands 2022.
    https://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
  • The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), in collaboration with Hall G, Schink T, Xie J. Triangulation. Amsterdam, The Netherlands 2022.
    https://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
  • The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), in collaboration with Hall G, Schink T, Li X. Use of an active comparator. Amsterdam, The Netherlands 2022.
    https://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
  • The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), in collaboration with Hallas J, Ehrenstein V, Hall G, Schink T, Klungel O. Methods to address bias. Amsterdam, The Netherlands 2020.
    http://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml
  • Books

  • Sturkenboom MCJM, Schink T, editors. Databases for pharmacoepidemiological research. Cham: Springer; 2021.
    https://doi.org/10.1007/978-3-030-51455-6.
  • Book chapters

  • Enders D, Schink T, Stürmer T. Medicaid and Medicare. In: Sturkenboom MCJM, Schink T, editors. Databases for pharmacoepidemiological research. Cham: Springer. 2021. S. 231-242.
    https://doi.org/10.1007/978-3-030-51455-6_19
  • Haug U, Schink T. German Pharmacoepidemiological Research Database (GePaRD). In: Sturkenboom MCJM, Schink T, editors. Databases for pharmacoepidemiological research. Cham: Springer. 2021. S. 119-124.
    https://doi.org/10.1007/978-3-030-51455-6_8
  • Presentations at scientific meetings/conferences

  • Schink T, Kollhorst B, Haug U. Antithyroid drug use before and during pregnancy: Assessment of switching patterns and changes over time. 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 23-27 August 2023, Halifax, Canada. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2023;32(S1):8-9)
  • Schink T, Wentzell N, Dathe K, Onken M, Haug U. Fetotoxicity of RAAS-inhibitors. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 16-17 September 2020, online presentation. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2020;29(S3):3705)
  • Schink T, Haug U. Estimation of the beginning of pregnancies ending in stillbirths. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2019;28(S2):479)
  • Presentations at scientific meetings/conferences (invited)

  • Schink T. Use of insurance data to study drug utilization in children with congenital malformations. Conference "Health and Education Outcomes of Children Across Europe with Congenital Anomalies" - EUROlinkCAT Conference, 7-8 April 2022, online presentation.
  • Schink T. Establishment of a framework to study the utilization and safety of drugs during pregnancy in the German Pharmacoepidemiology Research Database (GePaRD). Basel Epidemiology Seminar (BES), 25 March 2021, online presentation.
  • Schink T. Internal validation of outcomes in health databases. 8th Bordeaux Pharmacoepidemiology Festival, 21-23 May 2019, Bordeaux, France.
  • Posters at scientific meetings/conferences

  • Kollhorst B, Wentzell N, Niemeyer M, Haug U, Schink T. Identification of pregnancies without a recorded outcome in German claims data. 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 23-27 August 2023, Halifax, Canada. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2023;32(S1):516-517)
  • Schink T, Braitmaier M, Haug U. Long-term outcomes of children exposed to RAAS-inhibitors during pregnancy. 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 23-27 August 2023, Halifax, Canada. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2023;32(S1):527-528)
  • Wentzell N, Kollhorst B, Schink T. Time trends of HIV treatment in girls and women of childbearing age in Germany. 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 23-27 August 2023, Halifax, Canada. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2023;32(S1):523)
  • Witzleb AJ, Wentzell N, Schink T, Haug U. Exploratory analyses of modafinil utilization during pregnancy and diagnoses of malformations in the offspring. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 16-17 September 2020, online poster. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2020;29(S3):3704)

For further publications please follow this link:

  • Master of Science in Epidemiology, Johannes Gutenberg-Universiät, Mainz Pharmakoepidemiology, since 2013
  • Master of Science in Epidemiology, Ludwig-Maximilians-Universität, Munich Pharmakoepidemiology, since 2016

The responsibility for the content of this page lies with Tania Schink.

Tania Schink

Contact

Phone:
+49 (0)421 218-56-865